# Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

> **NCT03402503** · PHASE2 · COMPLETED · sponsor: **IntelGenx Corp.** · enrollment: 52 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Montelukast buccal film
- **OTHER:** Placebo buccal film

## Key facts

- **NCT ID:** NCT03402503
- **Lead sponsor:** IntelGenx Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-26
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-04-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402503, "Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03402503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*